期刊
CLINICAL INFECTIOUS DISEASES
卷 50, 期 8, 页码 1081-1083出版社
OXFORD UNIV PRESS INC
DOI: 10.1086/652237
关键词
-
资金
- Cubist
- Johnson Johnson
- Wyeth Pharmaceuticals
- Bayer Pharmaceuticals
- Cerexa
- Nabriva
- Trius
- Pfizer
- Merck
- Astellas
- Gilead
- Enzon
- Novartis
The time has come for a global commitment to develop new antibacterial drugs. Current data document the impending disaster due to the confluence of decreasing investment in antibacterial drug research and development concomitant with the documented rapid increase in the level of resistance to currently licensed drugs. Despite the good faith efforts of many individuals, professional societies, and governmental agencies, the looming crisis has only worsened over the past decade.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据